Global News

SimpleTrials expands contracts and payments feature set

Wednesday, August 23, 2017

Trial By Fire Solutions, a provider of on-demand, web-based clinical trial management solutions that improve planning, execution and tracking of clinical studies, has released SimpleTrials 2.0, a clinical trial management system (CTMS) with new features such as site contracts and payments management. The release also offers updated subscription plans for the SimpleTrials CTMS to meet a greater variety of user needs for teams of all sizes and budgets.

[Read More]

Ethris, AstraZeneca to develop mRNA therapies for respiratory diseases

Tuesday, August 22, 2017

Ethris, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on developing new stabilized non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM RNA technology.

[Read More]

Champions Oncology, AstraZeneca collaborate

Tuesday, August 22, 2017

Champions Oncology, a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in AstraZeneca’s oncology R&D programs in breast and lung cancer, in addition to being added to Champions’ existing TumorGraft bank for translational oncology research for academic and industry customers. Champions’ global network of collaborating sites will be leveraged to support this multi-year initiative.

[Read More]

Novartis, Medicines For Malaria Venture launch KAF156 trial in Africa

Tuesday, August 22, 2017

Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the efficacy of KAF156 in combination with a new, improved formulation of the existing antimalarial lumefantrine. The first trial center is operational in Mali and will be followed by sixteen additional centers across a total of nine countries in Africa and Asia over the next few months.

[Read More]

FDA approves Ironwood’s Duzallo for hyperuricemia related to gout

Tuesday, August 22, 2017

Ironwood Pharmaceuticals announced Duzallo was approved by the FDA as a once-daily oral treatment for hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone. Duzallo is not recommended for the treatment of asymptomatic hyperuricemia. Ironwood expects Duzallo to be commercially available early in the fourth quarter of 2017.

[Read More]

BioLineRx plans phase III BL-8040 registrational study of stem cell mobilization

Tuesday, August 22, 2017

BioLineRx, a clinical-stage biopharmaceutical company focused on oncology and immunology, announced the filing of regulatory submissions required to commence a randomized, controlled phase III registrational trial of BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. The trial, named GENESIS, is expected to commence by the end of 2017, following receipt of regulatory approvals.

[Read More]

iBIO Institute announces iCON Awards honorees

Tuesday, August 22, 2017

The iBIO Institute announced the four honorees of the eleventh annual iCON Awards—a prestigious honor for life sciences educators, researchers and civic visionaries. The iCON Awards celebrate the accomplishments of outstanding innovators and leaders whose work provides the basis for biotechnology developments worldwide.

[Read More]

Blade Therapeutics appoints Dr. Maria E. Fuentes EVP, Research

Tuesday, August 22, 2017

Blade Therapeutics, a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs, announced the appointment of Maria E. Fuentes, Ph.D., as Executive Vice President, Research. In this newly established position, Dr. Fuentes will lead Blade’s anti-fibrotic programs in preclinical testing. Blade’s flagship program, focused on a small molecule cysteine protease inhibitor, is expected to enter IND-enabling studies by year-end 2017.

[Read More]